Tenofovir Alafenamide (TAF) as Long-Term Therapy for Chronic Hepatitis B: Is It the Best Choice?

Tenofovir Alafenamide (TAF) as Long-Term Therapy for Chronic Hepatitis B: Is It the Best Choice?

-

Bibliographic Details
Main Author:	Irsan Hasan
Format:	Article
Language:	English
Published:	Interna Publishing 2022-12-01
Series:	The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Online Access:	https://www.ina-jghe.com/index.php/jghe/article/view/889

Similar Items

Evaluation Effect of Tenofovir Alafenamide (TAF) in Long-Term Therapy for Chronic Hepatitis B: A Systematic Review
by: Rada Citra Saputra, et al.
Published: (2022-12-01)

Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B
by: Tomohiro Nishikawa, et al.
Published: (2024-02-01)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
by: Chih-Wen Huang, et al.
Published: (2023-03-01)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
by: Tomoya Sano, et al.
Published: (2021-03-01)

One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B
by: Yi-Cheng Chen, MD, et al.
Published: (2022-06-01)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
by: Hung-Yao Lin, et al.
Published: (2022-04-01)

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
by: Hyeyeon Hong, et al.
Published: (2024-01-01)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020-12-01)

Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
by: Liu QM, et al.
Published: (2021-10-01)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
by: Young-Suk Lim, et al.
Published: (2023-10-01)

Cost-effectiveness of tenofovir alafenamide and entecavir in chronic hepatitis B in Saudi Arabia
by: Ahmed Al-Jedai
Published: (2024-01-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques
by: G. J. Gatto, et al.
Published: (2022-07-01)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
by: He J, et al.
Published: (2023-06-01)

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
by: Pin-Nan Cheng, et al.
Published: (2024-04-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV
by: Michał Łomiak, et al.
Published: (2023-09-01)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
by: Shun Ishido, et al.
Published: (2023-08-01)

Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
by: Ruth Byrne, et al.
Published: (2018-07-01)

Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024-02-01)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
by: Kento Inada, et al.
Published: (2021-09-01)

Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide☆
by: Ming-Lun Yeh, et al.
Published: (2022-07-01)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
by: Leah M. Johnson, et al.
Published: (2019-07-01)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
by: Pei-Yuan Su, et al.
Published: (2021-11-01)

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
by: Zekun Liu, et al.
Published: (2023-11-01)

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
by: Fa- Da Wang, et al.
Published: (2023-09-01)

Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model
by: Chun-Huang Lai, et al.
Published: (2024-02-01)

Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia
by: Faisal M Sanai, et al.
Published: (2024-01-01)

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
by: Hyeyeon Hong, et al.
Published: (2024-04-01)

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
by: Lanqing Li, et al.
Published: (2023-06-01)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
by: Chanie Wassner PharmD, BCCCP, BCIDP, et al.
Published: (2020-04-01)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023-06-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Long-Term Evaluation of Changes in Kidney Function after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients Living with HIV
by: Jared M. Gilbert, et al.
Published: (2022-11-01)

Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study
by: Wenting Peng, et al.
Published: (2023-05-01)

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
by: Joonho Jeong, et al.
Published: (2022-04-01)

P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS
by: Wai Kay Seto, et al.
Published: (2023-03-01)

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
by: Man Li, et al.
Published: (2023-03-01)

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis
by: Abdulmajeed Alharbi
Published: (2023-05-01)